Table 2.

Genotype and allele frequencies for each trial

Trials and cohorts*nCYP1B1 genotype
Allele frequencies§
Reference
*1/*1*1/*3*3/*3pq
Docetaxel-treated cohort (n = 52)
Docetaxel alone257 (28.0)13 (52.0)5 (20.0)0.540.46(14)
Docetaxel, estramustine, and thalidomide204 (20.0)12 (60.0)4 (20.0)0.500.50(16)
Docetaxel and prednisone71 (14.3)5 (71.4)1 (14.3)0.500.50(17)
Pharmacokinetics cohort (n = 23)
Docetaxel and prednisone237 (30.4)9 (39.1)7 (30.4)0.500.50(22)
Non-docetaxel-treated cohort (n = 145)
Suramin alone3611 (30.5)19 (52.7)6 (16.7)0.570.43(18)
Suramin and aminoglutethimide278 (29.6)16 (59.3)3 (11.1)0.590.41(19)
Suramin, leuprolide, and flutamide**414 (9.8)26 (63.4)11 (26.8)0.410.59(20)
Thalidomide alone††4112 (29.3)16 (39.0)13 (31.7)0.490.51(21)
  • * All patients are Caucasian unless otherwise noted.

  • One African American (carrying *3/*3), one Asian (carrying *1/*3), and one patient of unknown race (carrying *1/*3) are included.

  • Number of patients with percentage in parenthesis.

  • § Hardy-Weinberg notation for allele frequencies (p, frequency for wild-type allele; q, frequency for variant allele).

  • Three African Americans (one carrying *1/*3 and two carrying *3/*3), one Asian (carrying *1/*1), and one patient of unknown race (carrying *1/*3) are included.

  • One Asian is included (carrying *1/*1).

  • ** Three African Americans were included (two carrying *1/*1 and one carrying *3/*3).

  • †† One African American was included (carrying *1/*3).